Cargando…

Regional siderosis: a new challenge for iron chelation therapy

The traditional role of iron chelation therapy has been to reduce body iron burden via chelation of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary routes. In their present use for hemosiderosis, chelation regimens might not be suitable for treating disorders o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabantchik, Zvi Ioav, Munnich, Arnold, Youdim, Moussa B., Devos, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875873/
https://www.ncbi.nlm.nih.gov/pubmed/24427136
http://dx.doi.org/10.3389/fphar.2013.00167
_version_ 1782297419999870976
author Cabantchik, Zvi Ioav
Munnich, Arnold
Youdim, Moussa B.
Devos, David
author_facet Cabantchik, Zvi Ioav
Munnich, Arnold
Youdim, Moussa B.
Devos, David
author_sort Cabantchik, Zvi Ioav
collection PubMed
description The traditional role of iron chelation therapy has been to reduce body iron burden via chelation of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary routes. In their present use for hemosiderosis, chelation regimens might not be suitable for treating disorders of iron maldistribution, as those are characterized by toxic islands of siderosis appearing in a background of normal or subnormal iron levels (e.g., sideroblastic anemias, neuro- and cardio-siderosis in Friedreich ataxia- and neurosiderosis in Parkinson's disease). We aimed at clearing local siderosis from aberrant labile metal that promotes oxidative damage, without interfering with essential local functions or with hematological iron-associated properties. For this purpose we introduced a conservative mode of iron chelation of dual activity, one based on scavenging labile metal but also redeploying it to cell acceptors or to physiological transferrin. The “scavenging and redeployment” mode of action was designed both for correcting aberrant iron distribution and also for minimizing/preventing systemic loss of chelated metal. We first examine cell models that recapitulate iron maldistribution and associated dysfunctions identified with Friedreich ataxia and Parkinson's disease and use them to explore the ability of the double-acting agent deferiprone, an orally active chelator, to mediate iron scavenging and redeployment and thereby causing functional improvement. We subsequently evaluate the concept in translational models of disease and finally assess its therapeutic potential in prospective double-blind pilot clinical trials. We claim that any chelator applied to diseases of regional siderosis, cardiac, neuronal or endocrine ought to preserve both systemic and regional iron levels. The proposed deferiprone-based therapy has provided a paradigm for treating regional types of siderosis without affecting hematological parameters and systemic functions.
format Online
Article
Text
id pubmed-3875873
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38758732014-01-14 Regional siderosis: a new challenge for iron chelation therapy Cabantchik, Zvi Ioav Munnich, Arnold Youdim, Moussa B. Devos, David Front Pharmacol Pharmacology The traditional role of iron chelation therapy has been to reduce body iron burden via chelation of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary routes. In their present use for hemosiderosis, chelation regimens might not be suitable for treating disorders of iron maldistribution, as those are characterized by toxic islands of siderosis appearing in a background of normal or subnormal iron levels (e.g., sideroblastic anemias, neuro- and cardio-siderosis in Friedreich ataxia- and neurosiderosis in Parkinson's disease). We aimed at clearing local siderosis from aberrant labile metal that promotes oxidative damage, without interfering with essential local functions or with hematological iron-associated properties. For this purpose we introduced a conservative mode of iron chelation of dual activity, one based on scavenging labile metal but also redeploying it to cell acceptors or to physiological transferrin. The “scavenging and redeployment” mode of action was designed both for correcting aberrant iron distribution and also for minimizing/preventing systemic loss of chelated metal. We first examine cell models that recapitulate iron maldistribution and associated dysfunctions identified with Friedreich ataxia and Parkinson's disease and use them to explore the ability of the double-acting agent deferiprone, an orally active chelator, to mediate iron scavenging and redeployment and thereby causing functional improvement. We subsequently evaluate the concept in translational models of disease and finally assess its therapeutic potential in prospective double-blind pilot clinical trials. We claim that any chelator applied to diseases of regional siderosis, cardiac, neuronal or endocrine ought to preserve both systemic and regional iron levels. The proposed deferiprone-based therapy has provided a paradigm for treating regional types of siderosis without affecting hematological parameters and systemic functions. Frontiers Media S.A. 2013-12-31 /pmc/articles/PMC3875873/ /pubmed/24427136 http://dx.doi.org/10.3389/fphar.2013.00167 Text en Copyright © 2013 Cabantchik, Munnich, Youdim and Devos. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cabantchik, Zvi Ioav
Munnich, Arnold
Youdim, Moussa B.
Devos, David
Regional siderosis: a new challenge for iron chelation therapy
title Regional siderosis: a new challenge for iron chelation therapy
title_full Regional siderosis: a new challenge for iron chelation therapy
title_fullStr Regional siderosis: a new challenge for iron chelation therapy
title_full_unstemmed Regional siderosis: a new challenge for iron chelation therapy
title_short Regional siderosis: a new challenge for iron chelation therapy
title_sort regional siderosis: a new challenge for iron chelation therapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875873/
https://www.ncbi.nlm.nih.gov/pubmed/24427136
http://dx.doi.org/10.3389/fphar.2013.00167
work_keys_str_mv AT cabantchikzviioav regionalsiderosisanewchallengeforironchelationtherapy
AT munnicharnold regionalsiderosisanewchallengeforironchelationtherapy
AT youdimmoussab regionalsiderosisanewchallengeforironchelationtherapy
AT devosdavid regionalsiderosisanewchallengeforironchelationtherapy